Laboratoires Negma (hereinafter referred to as “Negma”) is the exclusive licensee of European patent No. 0 520 414 which relates to a method for the preparation of diacetylrhein (also called diacerein) having a specific degree of purity as well as diacetylrhein obtained by this process and a pharmaceutical composition containing this compound. Such European patent was first filed…

Preliminary injunctions in patent disputes can be a very effective weapon to fight against free riders on the one hand but are equally hurtful for defendants being at-tacked unjustifiably on the other hand. Such preliminary injunctions, especially when granted on an ex parte basis, can simply hinder the defendant to conduct business on the market….

The Court of Appeal dismissed Krka’s appeal against a decision of the Oslo Court of Enforcement and Execution, which granted AstraZeneca a preliminary injunction preventing Krka from marketing its generic esomeprazole product in Norway. The Court of Appeal held that the esomeprazole salt in Krka’s generic product with an optical purity of 98,8-99,4% was “an…

The requisite of “imminence” introduced by Directive 2004/48/EC, coupled with the measures approved by the Ministry of Health to speed-up the administrative steps necessary to launch generics, has placed owners of patents that protect chemical and/or pharmaceutical products at a crossroads: if they file an application for a preliminary injunction before the generic medicament has…

by Miriam Büttner In a recent decision of 15 September 2011 (ref. no. 4b O 99/11) the District Court of Düsseldorf (LG Düsseldorf) found that a non-final decision of the utility model cancel-lation division of the German Patent and Trademark Office (GPTO), with which the utility model was declared (partially) invalid, is not a sufficient…

If incorrect pre-litigation behavior of only one of the parties (in this case evasive and conflicting answers to warning letters of a patentee) leads to unnecessary litigation, the court costs and legal expenses of the counterparty have to be imposed entirely on the party that acted incorrectly. Click here for the full text of this case. A…

On 11 November 2011 the IP Chamber of the Court of Rome granted the motion for preliminary injunction requested by Novartis AG and Novartis Farma S.p.A. against Mylan S.p.A. on the basis of Novartis’ Italian valsartan and hydrochlorothiazide SPC, the active ingredients in Novartis’ Co-Diovan medicinal product (which is marketed in Italy as Co-Tareg). The…

With this groundbreaking decision of the CJEU, the parties entitled to injunctive relief are provided with the opportunity to obtain not only an enforceable injunction, but if the injunction is violated, they can also ask the original court to impose disciplinary fines on the defendant in a simple, fast and cost-efficient manner and then enforce these fines in other EU member states, as a rule at the domicile of the defendant.

The Court of Justice of the European Union in clarifying the phrase ‘civil and commercial matters’ in Article 1 of the Brussels I Regulation (No 44/2001) ruled that said Regulation is also applicable to court decisions that contain an order to pay penalties to ensure compliance with a judgment given in a civil and commercial…

The Danish Supreme Court upheld the Maritime and Commercial Court’s decision revoking an injunction against Teva issued by the Danish High Court. The Supreme Court ruled that a condition for the grant of an injunction is that it is “established or rendered probable” that the defendant will carry out the exact actions which are sought…